JAGUAR HEALTH, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
JAGUAR HEALTH, INC. (JAGX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $995.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-08-14
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2015-12-31 was $0.00.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2015-09-30 was $0.00.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2015-06-30 was $1.00M.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2015-03-31 was $202.52K.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2015 was $1.20M, a 95.67% increase from fiscal 2014.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2014 was $614.56K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2018-06-30 | $995.00K 10-Q · filed 2019-08-14 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $0.00 derived: sum of 2 quarters · filed 2017-02-15 | $1.00M derived: sum of 3 quarters · filed 2017-02-15 | $1.20M 10-K · filed 2017-02-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.00M derived: sum of 2 quarters · filed 2015-11-13 | $1.20M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.20M 10-Q · filed 2015-08-13 | ||
| 2015-03-31 | $202.52K 10-Q · filed 2015-06-26 | |||
| 2014-12-31 | $614.56K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |